Fung VS - Search Results

1

Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.

Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA. Antonini A, et al. Among authors: fung vs. Mov Disord. 2016 Apr;31(4):530-7. doi: 10.1002/mds.26528. Epub 2016 Jan 28. Mov Disord. 2016. PMID: 26817533 Free PMC article. Clinical Trial.

2

Brainstem myoclonus in a patient with non-dopa-responsive parkinsonism.

Clouston PD, Lim CL, Fung V, Yiannikas C, Morris JG. Clouston PD, et al. Mov Disord. 1996 Jul;11(4):404-10. doi: 10.1002/mds.870110409. Mov Disord. 1996. PMID: 8813220

3

Objective quantification of resting and activated parkinsonian rigidity: a comparison of angular impulse and work scores.

Fung VS, Burne JA, Morris JG. Fung VS, et al. Mov Disord. 2000 Jan;15(1):48-55. doi: 10.1002/1531-8257(200001)15:1<48::aid-mds1009>3.0.co;2-e. Mov Disord. 2000. PMID: 10634241

4

Treatment of Parkinson's disease.

Hely MA, Fung VS, Morris JG. Hely MA, et al. Among authors: fung vs. J Clin Neurosci. 2000 Nov;7(6):484-94. doi: 10.1054/jocn.2000.0766. J Clin Neurosci. 2000. PMID: 11029227 Review.

5

Movement disorder emergencies.

Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Kipps CM, et al. Among authors: fung vs. Mov Disord. 2005 Mar;20(3):322-34. doi: 10.1002/mds.20325. Mov Disord. 2005. PMID: 15584031 Review.

6

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group. Fung VS, et al. Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878. Mov Disord. 2009. PMID: 18846551 Clinical Trial.

7

Bradykinesia, muscle weakness and reduced muscle power in Parkinson's disease.

Allen NE, Canning CG, Sherrington C, Fung VS. Allen NE, et al. Among authors: fung vs. Mov Disord. 2009 Jul 15;24(9):1344-51. doi: 10.1002/mds.22609. Mov Disord. 2009. PMID: 19425085

8

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.

Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, Smith RA, Murphy MP, Taylor KM; Protect Study Group. Snow BJ, et al. Mov Disord. 2010 Aug 15;25(11):1670-4. doi: 10.1002/mds.23148. Mov Disord. 2010. PMID: 20568096 Clinical Trial.

9

The effects of an exercise program on fall risk factors in people with Parkinson's disease: a randomized controlled trial.

Allen NE, Canning CG, Sherrington C, Lord SR, Latt MD, Close JC, O'Rourke SD, Murray SM, Fung VS. Allen NE, et al. Among authors: fung vs. Mov Disord. 2010 Jul 15;25(9):1217-25. doi: 10.1002/mds.23082. Mov Disord. 2010. PMID: 20629134 Clinical Trial.

10

Postural sway approaches center of mass stability limits in Parkinson's disease.

Menant JC, Latt MD, Menz HB, Fung VS, Lord SR. Menant JC, et al. Among authors: fung vs. Mov Disord. 2011 Mar;26(4):637-43. doi: 10.1002/mds.23547. Epub 2011 Feb 10. Mov Disord. 2011. PMID: 21312283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

249 results

Search Page

Filters